Tyrosine Kinases / Adaptors
| CSTコード |
包装 |
希望納入価格(円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1645 | 100 μg | 16,000 | |
|
MET抗体製品一覧
| 使用目的 | |
| Phospho-Met (Tyr1234/1235) (Ser10) Antibody (#3077)の反応をブロックし、抗体の反応特異性を確認するために使用します |
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded HCC827 xenograft using Phospho-Met (Tyr1234/1235) (D26) Rabbit mAb #3077 in the presence of control peptide (left) or Phospho-Met (Tyr1234/1235) Blocking Peptide (right).
Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation of Tyr1234/1235 in the Met kinase domain is critical to kinase activation. Phosphorylation of Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon and breast. Thus, Met is an attractive cancer therapeutic and diagnostic target (6).
-
Weidner, K.M. et al. (1993)
J. Cell Biol.
121, 145-154.
-
Park, M. et al. (1986)
Cell
45, 895-904.
-
Bardelli, A. et al. (1997)
Oncogene
15, 3103-3111.
-
Taher, T.E. et al. (2002)
J. Immunol.
169, 3793-3800.
-
Schaeper, U. et al. (2000)
J. Cell Biol.
149, 1419-1432.
-
Traxler, P. et al. (2001)
Med. Res. Rev.
21, 499-512.